GlassScriptPhysician profile
Michael G Shaw
NPI 1073058020
$1,525.93
in general payments reported to CMS, 2019-2025
13 companies · $56.85 in 2025
The $56.85 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $559 · 2022: $524 · 2023: $117 · 2024: $269 · 2025: $56.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $307.12 | 2021-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $234.87 | 2022-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $207.96 | 2021-2024 | Invega Sustenna |
| Lundbeck LLC | $159.88 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $150.29 | 2021-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $134.36 | 2021-2023 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $107.99 | 2021-2025 | Abilify Asimtufii, Abilify Maintena |
| Avanir Pharmaceuticals, INC. | $74.60 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $48.96 | 2021 | |
| Acadia Pharmaceuticals INC | $33.51 | 2025 | Nuplazid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.93 | 2024 | |
| Abbvie INC. | $21.37 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.